Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia Pharmaceutical — Merger or Acquisition (March 2021)
15 slides from Vivesto Ab's merger presentation, Mar 1, 2021
Slide 1: Acquisition of Global Development and Commercialization Rights for Cantrixil
ACQUISITION OF GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR CANTRIXIL, A CLINICAL STAGE OVARIAN CANCER PROGRAM Building critical mass in the oncology pipeline FRANCOIS MARTELET, M.D., Chief Executive Officer REINHARD KOENIG, M.D., Acting Chief Scientific Officer 1 March 2021
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Today's speakers
Today’s speakers FRANCOIS MARTELET, M.D. REINHARD KOENIG, M.D. Chief Executive Officer Acting Chief Scientific Officer 3
Slide 4: Delivering our own "string of pearls" strategy
Delivering our own “string of pearls” strategy • Global rights to drug candidate Cantrixil (INN/TRX-E002-1) licensed from Kazia Therapeutics Limited (ASX:KZA) • Builds on Oasmia’s proven development and regulatory expertise in ovarian cancer • Evaluating potential for synergies with Apealea® and XR-
Slide 5: Cantrixil overview
Cantrixil overview • First-in-class, 3rd generation benzopyran, targeting CD 44+ cancers, initially ovarian cancer • Pre-clinical ‒ Activity against ovarian cancer stem cells (CSCs), a key driver of resistance ‒ Cantrixil monotherapy inhibits tumor growth in a model of aggressive ovarian cancer ‒ Ca
Slide 6: Ovarian cancer – major unmet need with high rate of recurrence
Ovarian cancer – major unmet need with high rate of recurrence Incidence1 27000 • Globally 295,000 women 26600 diagnosed in 2018 – 8th most 26500 common cancer in women1 26000 25500 • >70% of women have a relapse Incidence 25000 within three years from diagnosis2 24500 24500 24000 • $6.7 billion – f
Slide 7: Cancer stem cells have a key role in tumor recurrence & resistance
Cancer stem cells have a key role in tumor recurrence & resistance • Cancer Stem Cells (CSCs) able to self-renew, differentiate & initiate and maintain tumor growth • CSC are drug-resistant, leading to tumor recurrence & metastasis • Standard of care (SoC) is still platinum and taxane-based therapy
Slide 8: Potent anti-cancer activity seen in pre-clinical results
Potent anti-cancer activity seen in pre-clinical results Cantrixil: ✓ Destroys cancer stem cell spheroids ✓ Monotherapy inhibits tumor growth in aggressive ovarian cancer model ✓ Cantrixil + cisplatin combine effectively against chemo-resistant cancer cells in vitro and in vivo ✓ Anti-cancer activit
Slide 9: Multi-MoA may be key to overcome cisplatin-resistant cancer stem cells
Multi-MoA may be key to overcome cisplatin-resistant cancer stem cells • Mitotic arrest directly inhibits tubulin polymerization by binding to colchicine binding site on tubulin ‒ Studies of agents binding to colchicine site of tubulin incl. Cantrixil show pronounced anti cancer stem cell (CSC) acti
Slide 10: Positive phase I safety & pharmacokinetics results
Positive phase I safety & pharmacokinetics results Safety • Maximum tolerated dose (MTD) of 5 mg/kg established (within predicted therapeutic range) • Most common drug-related adverse events, although not generally dose limiting, were abdominal pain (27%), fatigue (13%), vomiting (10%) and nausea (1
Slide 11: Phase I study shows positive efficacy & safety signals
Phase I study shows positive efficacy & safety signals Population: Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer Primary objective achieved, determining maximum tolerated dose (MTD) 16 patients evaluable for efficacy • 1 complete response (CR) • 2 partial re
Slide 12: Building critical mass in our oncology portfolio
Building critical mass in our oncology portfolio Registration / Commercial Product Indication Pre-clinical Phase I Phase II Phase III approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer EU / EEA Paclical® (paclitaxel) Ovarian cancer USA Cantrixil Ovarian cancer Global Docetaxe
Slide 13: Agreement terms & next steps
Agreement terms & next steps Agreement terms Next steps • Upfront consideration of US$4 million • Peer-reviewed publication of full Phase I • Development & milestones of up to US$42 million results • Undisclosed sales-based royalties in line with • Phase 2 initiation anticipated in 2022 industry sta
Slide 14: Cantrixil – an exciting opportunity with potential platform synergies
Cantrixil – an exciting opportunity with potential platform synergies • Cantrixil: ‒ First-in-class tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44-), both resistant to standard chemotherapies ‒ Potential to improv
Slide 15: Delivering our strategy to provide sustainable long-term growth
Delivering our strategy to provide sustainable, growth long-term growth • First in planned series of “string of pearls” acquisitions & in-licensing deals • Strong cash position with SEK 287m (YE 2020) Delivering our four-pillar strategy for growth 1 2 3 4 Execute the Partnering & clinical Clinical I
Oasmia Pharmaceutical — Merger or Acquisition (March 2021) on 6ix